XENE: Wellington reports 2.17M shares, 2.83% in Xenon
Xenon Pharmaceuticals (XENE) received a Schedule 13G/A disclosing that Wellington-affiliated filers report beneficial ownership of 2,174,761 common shares, representing 2.83% of the class.
Rhea-AI Filing Summary
Xenon Pharmaceuticals (XENE) received a Schedule 13G/A disclosing that Wellington-affiliated filers report beneficial ownership of 2,174,761 common shares, representing 2.83% of the class. The filing shows no sole voting or dispositive power and shared voting power of 2,146,462, with shared dispositive power of 2,174,761, indicating the positions are managed jointly by Wellington entities.
The filing states these securities are owned of record by Wellington clients and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer. No client is identified as owning more than 5% of the class.
Positive
- Transparent institutional disclosure: Wellington affiliates reported holdings and voting arrangements, improving public visibility of ownership.
- Passive ownership certified: The filing states the shares are held in the ordinary course and not for control, signaling no activist intent.
Negative
- None.
Insights
TL;DR: Wellington-affiliated advisers report a passive institutional stake of 2.17M shares (2.83%), held for clients with shared voting power.
The holding size is meaningful as an institutional position but remains below 5%, consistent with a passive Schedule 13G filing rather than an activist Schedule 13D. Shared voting power of 2,146,462 versus total beneficial ownership of 2,174,761 suggests coordinated management across Wellington entities. The filing explicitly states holdings are in the ordinary course and not for control, which reduces near-term corporate governance disruption risk.
TL;DR: Reporting reflects routine institutional disclosure; no indication Wellington seeks to influence control.
The Schedule 13G/A classification and the certification language confirm the position is passive and client-directed. The disclosure of shared voting and dispositive power clarifies which Wellington affiliates participate in decision-making, supporting transparency for Xenon's shareholder registry. Absence of any >5% client and the statement that securities are not held to change control limit immediate governance implications.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who filed the Schedule 13G/A for Xenon Pharmaceuticals (XENE)?
What percentage of XENE does Wellington own according to the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.